The Netherlands
Tessellate Bio, a biotechnology startup founded in 2020, is at the forefront of precision oncology. The company, with its slogan "Redefining Synthetic Lethality beyond HRD", is pioneering the development of novel cancer treatments by targeting previously unexplored pathways beyond HRD.
Operating out of its headquarters in The Netherlands and research labs in the Stevenage Bioscience Catalyst in the UK, the company is focused on turning cancer patients into survivors. Tessellate Bio stands out in the biotech sector by being at a preclinical stage yet attracting significant investments.
In its latest financing effort, the company secured a substantial €8.00M Seed Round investment as of October 17, 2023. This funding was led by prominent life science investors, BioGeneration Ventures and Forbion. The backing from these seasoned investors underscores confidence in Tessellate Bio's innovative approach and potential to disrupt the oncology field.
